United States Drug Patent 5,424,295: Claim Scope, Expiration, Orange Book Status, and Nelarabine Patent Landscape

U.S. Patent No. 5,424,295 covers nelarabine, its pharmaceutically acceptable salts, selected 5'-ester derivatives, and pharmaceutical compositions containing those compounds. The patent was assigned to Glaxo Group Limited and protected the chemical entity later commercialized as Arranon. Its U.S. patent term expired in 2012, with pediatric exclusivity extending regulatory protection beyond the patent term. The patent no longer creates an enforceable U.S. barrier to generic nelarabine entry.

What drug does U.S. Patent 5,424,295 protect?

The principal compound in U.S. Patent 5,424,295 is 9-β-D-arabinofuranosyl-2-amino-6-methoxy-9H-purine, commonly known as nelarabine.

Nelarabine is a prodrug of ara-G, or 9-β-D-arabinofuranosylguanine. It is converted in vivo to ara-G, which is subsequently phosphorylated to active ara-G triphosphate. The active metabolite interferes with DNA synthesis and has particular activity against malignant T lymphoblasts.

Item	Description
Active ingredient	Nelarabine
Chemical name	9-β-D-arabinofuranosyl-2-amino-6-methoxy-9H-purine
Formula	C12H16N6O4
Molecular weight	308.29 g/mol
Therapeutic class	Antimetabolite, purine nucleoside analogue
FDA product	Arranon
Approved dosage form	Intravenous injection
FDA sponsor	GlaxoSmithKline
Main indication	Relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma
FDA approval	2005
Patent	U.S. Patent No. 5,424,295

Nelarabine is chemically distinct from ara-G because the 6-position oxygen of the purine ring is methylated. That methyl group improves prodrug properties and permits administration of the compound as nelarabine rather than directly administering ara-G.

What are the claims of U.S. Patent 5,424,295?

The patent contains eight claims directed to three categories: the nelarabine molecule, two ester derivatives, and pharmaceutical compositions.

Claims directed to nelarabine

Claim 1 covers the free-base compound:

9-β-D-arabinofuranosyl-2-amino-6-methoxy-9H-purine.

Claims 6, 7, and 8 extend protection to salts and compositions:

Claim 6 covers pharmaceutically acceptable salts of nelarabine.
Claim 7 covers a pharmaceutical composition containing nelarabine and a pharmaceutically acceptable carrier.
Claim 8 covers a pharmaceutical composition containing a pharmaceutically acceptable salt of nelarabine and a pharmaceutically acceptable carrier.

These claims collectively cover the active pharmaceutical ingredient, its salt forms, and medicinal compositions containing either form.

Claims directed to the 5'-acetate derivative

Claim 2 covers:

2-Amino-6-methoxy-9-(5-O-acetyl-β-D-arabinofuranosyl)-9H-purine.

This is the 5'-O-acetyl derivative of nelarabine. The claim is a composition-of-matter claim. It does not require a pharmaceutical use, formulation, dosage, or manufacturing process.

Claim 3 covers pharmaceutically acceptable salts of the 5'-O-acetyl derivative.

Claim 4 covers pharmaceutical compositions containing the 5'-O-acetyl derivative or one of its pharmaceutically acceptable salts.

Claim directed to the methyl succinate derivative

Claim 5 covers:

2-Amino-6-methoxy-9-(5-O-(4-methoxy-4-oxobutyryl)-β-D-arabinofuranosyl)-9H-purine, or a pharmaceutically acceptable salt thereof.

The 4-methoxy-4-oxobutyryl group is a 5'-O-succinic acid monomethyl ester substituent. This claim covers a second ester derivative and its salts.

How broad are the claims in U.S. Patent 5,424,295?

The patent estate is chemically focused rather than platform-based. Its broadest practical claim is claim 1, which covers nelarabine as a defined small-molecule compound.

The claims do not broadly cover:

All purine nucleoside analogues
All ara-G prodrugs
All 6-substituted arabinosyl purines
All formulations for T-cell malignancies
All methods of treating leukemia with a purine analogue
Manufacturing processes in generic terms
Combination therapy with other oncology agents
Pharmaceutical compositions defined by a particular dosage or delivery system

The patent therefore protects the specific chemical structure and selected derivative forms. A product containing the same nelarabine active ingredient would fall within the literal scope of claim 1, regardless of whether the manufacturer used a different synthetic route, excipient system, container, or infusion presentation.

Free base and salt coverage

Claims 1 and 6 separate the free base from pharmaceutically acceptable salts. A generic manufacturer cannot avoid claim 6 merely by isolating or formulating nelarabine as a salt. Conversely, a product using the neutral compound implicates claim 1.

The claims do not identify an exclusive list of salts. The phrase “pharmaceutically acceptable salt” generally reaches conventional acid-addition or related pharmaceutically suitable salt forms that satisfy the chemical and pharmaceutical limitations of the claim.

Composition claim limitations

Claims 4, 7, and 8 require a pharmaceutical composition and a pharmaceutically acceptable carrier. They are narrower than the corresponding compound claims because they require a formulated medicinal product.

A composition claim can be useful against a marketed dosage form, but it does not expand the underlying chemical scope. A product that contains nelarabine as an active ingredient remains exposed to claim 1 even if it does not use the same carrier system described in the patent specification.

What formulations are protected by U.S. Patent 5,424,295?

The patent claims pharmaceutical compositions containing:

Nelarabine;
A pharmaceutically acceptable salt of nelarabine;
The 5'-O-acetyl derivative; or
A pharmaceutically acceptable salt of the 5'-O-acetyl derivative.

The claims do not require a specific excipient, buffer, concentration, pH, vial, infusion bag, preservative, or administration schedule. The carrier limitation is functional and pharmaceutical rather than formulation-specific.

Arranon is supplied as an intravenous solution. The patent’s composition claims could therefore read on a medicinal formulation containing nelarabine, but they do not appear to create a separate, enduring formulation patent position comparable to a patent claiming a proprietary vehicle, sustained-release system, or device.

When did U.S. Patent 5,424,295 expire?

The patent issued on June 13, 1995, from an application claiming priority to an earlier foreign filing. Its listed U.S. patent expiration date was September 7, 2012. The patent is expired and cannot currently block manufacture, sale, or use of nelarabine in the United States under the patent statute.

Event	Date
Earliest priority filing	September 1991
U.S. application	1992
U.S. patent issued	June 13, 1995
U.S. patent number	5,424,295
Listed patent expiration	September 7, 2012
Arranon FDA approval	2005
Orphan-drug exclusivity period	Seven years from approval
Pediatric exclusivity	Six-month extension associated with FDA pediatric requirements

The patent term was therefore substantially concurrent with the early commercial life of Arranon. Any six-month pediatric exclusivity did not revive the patent. Pediatric exclusivity extends certain FDA regulatory protections; it does not extend the patent’s enforceable term.

What is the Orange Book status of nelarabine?

The FDA listed U.S. Patent No. 5,424,295 in connection with Arranon. The listing identified the patent protecting the active ingredient and related product claims for the approved drug.

The Orange Book listing had practical significance before expiration because an abbreviated new drug application applicant could be required to address the patent through a Paragraph IV certification or wait for patent expiry. After expiration, the listing no longer creates a live patent infringement obstacle.

Orange Book issue	Effect for nelarabine
Listed patent	U.S. 5,424,295
Protected product	Arranon injection containing nelarabine
Patent status	Expired
Current 30-month stay risk	None based on this expired patent
Current patent-based launch block	None from U.S. 5,424,295
Regulatory exclusivity	Historical orphan-drug and pediatric protections
Approved use	T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma

An ANDA applicant seeking approval for nelarabine injection would generally address the listed patent according to its current status. Because the patent expired, a Paragraph IV challenge to obtain a commercial launch before patent expiry is no longer commercially relevant.

Were there Paragraph IV challenges to U.S. Patent 5,424,295?

The patent created a conventional Paragraph IV issue during the period before September 2012. A generic applicant could have certified that the patent was invalid, unenforceable, or would not be infringed. A Paragraph IV certification could have triggered patent litigation and, depending on timing, an FDA approval stay of up to 30 months.

The commercial value of such a challenge declined after:

The patent approached its September 2012 expiration;
The seven-year orphan-drug exclusivity period ended;
Pediatric exclusivity concluded; and
The remaining commercial market was limited to a rare hematologic oncology indication.

The expired status of the patent eliminates any current 30-month stay based on this patent. A later generic applicant would not need to defeat an enforceable claim in order to launch after expiration.

What patent litigation affects nelarabine?

U.S. Patent No. 5,424,295 does not create an active patent-litigation risk today. Its enforceable term ended in 2012.

The historical litigation risk was concentrated in the pre-expiration period and would have involved:

Infringement of claim 1 by a product containing nelarabine;
Infringement of claim 6 by a nelarabine salt;
Infringement of claims 7 and 8 by formulated products;
Potential infringement of claims 2 through 5 by the claimed ester derivatives; and
Hatch-Waxman litigation following a Paragraph IV certification.

There is no need for a current generic entrant to design around the core nelarabine molecule on account of this expired patent. A design-around remains relevant only for any separate, later-expiring patent covering a formulation, manufacturing process, dosage regimen, or other product feature.

How strong was the patent estate for nelarabine?

The patent estate was strong for the specific active ingredient during its term because claim 1 was a composition-of-matter claim. Composition claims ordinarily provide broader enforcement leverage than claims limited to a treatment method or formulation.

Its principal strengths were:

Direct coverage of nelarabine;
Separate salt coverage;
Product-composition claims;
Coverage of selected 5'-ester derivatives;
No dependency on a particular manufacturing route; and
Commercial alignment between the claimed molecule and the approved product.

Its limitations were equally clear:

The patent did not provide a broad purine-analogue platform;
It did not claim all methods of treating T-cell malignancies;
It did not provide a durable formulation or device barrier;
The core patent expired in 2012; and
Regulatory exclusivity was time-limited and separate from patent rights.

The estate was therefore strong but narrow: high blocking strength against the specific drug during the patent term, with limited residual protection after expiry.

What manufacturing and intellectual-property barriers remain?

The expired composition patent removes the principal U.S. chemical barrier. A generic manufacturer still must establish pharmaceutical equivalence, product quality, analytical control, sterility, stability, and manufacturing consistency for the injectable product.

Potential non-patent barriers include:

Low-volume oncology manufacturing economics;
Sterile injectable production capacity;
Validation of impurity profiles;
Control of degradation products;
Bioequivalence and comparative quality requirements;
Limited market size;
Hospital and oncology purchasing contracts; and
Pharmacovigilance obligations.

These are commercial and regulatory barriers, not continuing rights under U.S. Patent 5,424,295.

How does nelarabine compare with competing purine analogues?

Drug	Principal target or mechanism	Patent position relevant to nelarabine
Nelarabine	Prodrug converted to ara-G triphosphate	Core U.S. patent expired
Clofarabine	Purine nucleoside analogue	Separate patent estate and regulatory history
Fludarabine	Fluorinated purine analogue	Separate active ingredient and patent history
Cladribine	Purine nucleoside analogue	Separate composition and use claims
Cytarabine	Pyrimidine nucleoside analogue	Chemically distinct and separately regulated

Nelarabine’s differentiation is therapeutic rather than patent-based. It is specifically associated with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma, whereas many competing antimetabolites have broader or different hematologic indications.

Does nelarabine have biosimilar risk?

No. Nelarabine is a chemically synthesized small molecule, not a biologic. Biosimilar provisions under the Public Health Service Act do not apply.

The relevant competitive pathway is an ANDA for a generic version of the approved injectable product. Generic risk depends on FDA approval, pharmaceutical equivalence, manufacturing economics, and any later-expiring patents listed for the product, not on biosimilar interchangeability.

What is the geographic scope of U.S. Patent 5,424,295?

The patent provides rights only in the United States. It cannot directly prevent manufacture, sale, or use in Canada, Europe, Japan, Australia, or other jurisdictions.

The underlying invention may have been pursued through an international patent family. Each corresponding national patent must be assessed separately for:

Filing date;
Grant date;
Patent-term adjustment or extension;
Supplementary protection certificate status;
Claim scope;
Opposition or invalidity proceedings; and
Expiration date.

The expiration of U.S. Patent 5,424,295 does not establish that every foreign counterpart has expired, although the age of the family means that most ordinary patent terms would also have ended or be near expiry.

What licensing deals and commercial rights affected nelarabine?

Arranon was commercialized by GlaxoSmithKline following development by the Glaxo Wellcome organization. The relevant commercial rights were held within the Glaxo corporate group rather than being based on a later external license necessary to practice U.S. Patent No. 5,424,295.

The patent’s commercial value was tied to the approved Arranon product and its orphan oncology indication. No continuing license is required to practice the expired U.S. patent.

Key Takeaways

U.S. Patent No. 5,424,295 covers nelarabine, its pharmaceutically acceptable salts, two 5'-ester derivatives, and related pharmaceutical compositions.
Claim 1 is the principal blocking claim because it covers the nelarabine molecule itself.
Claims 6 through 8 cover salts and pharmaceutical compositions containing nelarabine.
Claims 2 through 5 cover 5'-O-acetyl and 5'-O-succinate derivative forms.
The listed U.S. patent expiration date was September 7, 2012.
Arranon received FDA approval in 2005 for T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
Historical orphan-drug and pediatric exclusivity protections were separate from the patent and have ended.
The patent is expired and presents no current U.S. patent-based launch block for a nelarabine generic.
Nelarabine is a small molecule, so biosimilar rules do not apply.
Current risk analysis should focus on FDA approval requirements, sterile injectable manufacturing, market size, and any later-expiring product or process patents.

FAQs About U.S. Patent 5,424,295 and Nelarabine

Is U.S. Patent 5,424,295 still enforceable?

No. The patent’s listed U.S. expiration date was September 7, 2012.

Does claim 1 cover Arranon?

Yes. Claim 1 covers nelarabine, the active ingredient in Arranon.

Can a company manufacture nelarabine without using the patented synthesis?

Yes. The patent’s principal claim is directed to the compound, not only to a particular manufacturing process. The patent itself is now expired.

Did pediatric exclusivity extend the nelarabine patent?

No. Pediatric exclusivity extends certain FDA regulatory protections for six months. It does not extend the enforceable patent term.

Is a new nelarabine product subject to biosimilar approval?

No. Nelarabine is a synthetic small molecule. A competing product would generally use the generic-drug pathway rather than the biosimilar pathway.

References

Food and Drug Administration. (2005). Arranon (nelarabine) injection prescribing information. U.S. Department of Health and Human Services.
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
Glaxo Group Limited. (1995). 2-Amino-6-methoxy-9-beta-D-arabinofuranosyl-9H-purine and derivatives (U.S. Patent No. 5,424,295). United States Patent and Trademark Office.
National Library of Medicine. (n.d.). Nelarabine. DailyMed.
United States Patent and Trademark Office. (2024). Patent term adjustment and patent term information. U.S. Department of Commerce.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	8712745	May 30, 1987

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0294114	⤷ Start Trial	91370	Luxembourg	⤷ Start Trial
European Patent Office	0294114	⤷ Start Trial	C00294114/01	Switzerland	⤷ Start Trial
European Patent Office	0294114	⤷ Start Trial	07C0058	France	⤷ Start Trial
European Patent Office	0294114	⤷ Start Trial	300302	Netherlands	⤷ Start Trial
European Patent Office	0294114	⤷ Start Trial	SPC/GB08/006	United Kingdom	⤷ Start Trial
European Patent Office	0294114	⤷ Start Trial	2007C/063	Belgium	⤷ Start Trial
European Patent Office	0294114	⤷ Start Trial	C300302	Netherlands	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,424,295

Summary for Patent: 5,424,295